275 related articles for article (PubMed ID: 21837775)
21. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.
Sandborn WJ; Travis S; Moro L; Jones R; Gautille T; Bagin R; Huang M; Yeung P; Ballard ED
Gastroenterology; 2012 Nov; 143(5):1218-1226.e2. PubMed ID: 22892337
[TBL] [Abstract][Full Text] [Related]
22. Long-term mesalamine maintenance in ulcerative colitis: which is more important? Adherence or daily dose.
Khan N; Abbas AM; Koleva YN; Bazzano LA
Inflamm Bowel Dis; 2013 May; 19(6):1123-9. PubMed ID: 23514878
[TBL] [Abstract][Full Text] [Related]
23. Once daily vs multiple daily mesalamine therapy for mild to moderate ulcerative colitis: a meta-analysis.
Li W; Zhang ZM; Jiang XL
Colorectal Dis; 2016 Jul; 18(7):O214-23. PubMed ID: 27214762
[TBL] [Abstract][Full Text] [Related]
24. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol.
Prantera C; Kohn A; Campieri M; Caprilli R; Cottone M; Pallone F; Savarino V; Sturniolo GC; Vecchi M; Ardia A; Bellinvia S
Aliment Pharmacol Ther; 2009 Nov; 30(9):908-18. PubMed ID: 19678813
[TBL] [Abstract][Full Text] [Related]
25. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis.
Kane S; Huo D; Magnanti K
Clin Gastroenterol Hepatol; 2003 May; 1(3):170-3. PubMed ID: 15017487
[TBL] [Abstract][Full Text] [Related]
26. Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors.
Zakko SF; Gordon GL; Murthy U; Sedghi S; Pruitt R; Barrett AC; Bortey E; Paterson C; Forbes WP; Lichtenstein GR
Postgrad Med; 2016; 128(3):273-81. PubMed ID: 26861051
[TBL] [Abstract][Full Text] [Related]
27. Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis.
Bonovas S; Nikolopoulos GK; Piovani D; González-Lorenzo M; Pantavou K; Lytras T; Peyrin-Biroulet L; Danese S
Br J Clin Pharmacol; 2019 Oct; 85(10):2244-2254. PubMed ID: 31269287
[TBL] [Abstract][Full Text] [Related]
28. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.
Sandborn WJ; Korzenik J; Lashner B; Leighton JA; Mahadevan U; Marion JF; Safdi M; Sninsky CA; Patel RM; Friedenberg KA; Dunnmon P; Ramsey D; Kane S
Gastroenterology; 2010 Apr; 138(4):1286-96, 1296.e1-3. PubMed ID: 20064514
[TBL] [Abstract][Full Text] [Related]
29. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.
Sandborn WJ; Kamm MA; Lichtenstein GR; Lyne A; Butler T; Joseph RE
Aliment Pharmacol Ther; 2007 Jul; 26(2):205-15. PubMed ID: 17593066
[TBL] [Abstract][Full Text] [Related]
30. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
[TBL] [Abstract][Full Text] [Related]
31. Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis.
Osterman MT; Aberra FN; Cross R; Liakos S; McCabe R; Shafran I; Wolf D; Hardi R; Nessel L; Brensinger C; Gilroy E; Lewis JD;
Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1887-93.e3. PubMed ID: 24793028
[TBL] [Abstract][Full Text] [Related]
32. Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials.
Lichtenstein GR; Zakko S; Gordon GL; Murthy U; Sedghi S; Pruitt R; Merchant K; Bortey E; Forbes WP
Aliment Pharmacol Ther; 2012 Jul; 36(2):126-34. PubMed ID: 22617015
[TBL] [Abstract][Full Text] [Related]
33. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial.
Lang A; Salomon N; Wu JC; Kopylov U; Lahat A; Har-Noy O; Ching JY; Cheong PK; Avidan B; Gamus D; Kaimakliotis I; Eliakim R; Ng SC; Ben-Horin S
Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1444-9.e1. PubMed ID: 25724700
[TBL] [Abstract][Full Text] [Related]
34. Reformulation of an aminosalicylate: an example of the importance of pill burden on medical compliance rates.
Osterman MT; Lichtenstein GR
Methods Find Exp Clin Pharmacol; 2009; 31(1):41-6. PubMed ID: 19357797
[TBL] [Abstract][Full Text] [Related]
35. The problem of adherence to therapy in ulcerative colitis and the potential utility of multi-matrix system (MMX) technology.
Bezzio C; Fascì-Spurio F; Viganò C; Meucci G; Papi C; Saibeni S
Expert Rev Gastroenterol Hepatol; 2017 Jan; 11(1):33-41. PubMed ID: 27805459
[TBL] [Abstract][Full Text] [Related]
36. MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis.
Hu MY; Peppercorn MA
Expert Opin Pharmacother; 2008 Apr; 9(6):1049-58. PubMed ID: 18377346
[TBL] [Abstract][Full Text] [Related]
37. MMX mesalamine.
Baker DE
Rev Gastroenterol Disord; 2006; 6(3):146-52. PubMed ID: 16957657
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study.
Meucci G; Fasoli R; Saibeni S; Valpiani D; Gullotta R; Colombo E; D'Incà R; Terpin M; Lombardi G;
Inflamm Bowel Dis; 2012 Jun; 18(6):1006-10. PubMed ID: 21830282
[TBL] [Abstract][Full Text] [Related]
39. MMX Mesalamine for Induction and Maintenance Therapy in Mild-to-Moderate Ulcerative Colitis.
Hanauer SB; Lichtenstein GR; Kamm MA; Sandborn WJ; Lees KH; Barrett K; Karlstadt RG; Diebold R; Joseph RE
Gastroenterol Hepatol (N Y); 2009 Jul; 5(7):494-500. PubMed ID: 37967434
[TBL] [Abstract][Full Text] [Related]
40. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
